Amarin Corp Plc (AMRN)

[Bouf]

This is the primary Q that Amarin’s appellate counsel must pose to the CTA: if no one had previously studied the impact of using pure EPA in ester form to treat severe HTG (500+), and it was known in relevant medical/academic space that patients in this population were susceptible to spikes in LDL from all known treatments for severe HTG, why would a POSA expect that pure EPA would be able to reduce TG without pushing up LDL?